Study backs gene therapy for heart failure:
This article was originally published in Clinica
Collateral Therapeutics' angiogenesis-promoting gene has shown promise as a non-surgical treatment for heart failure, according to results from a placebo-controlled animal study in the March issue of Cardiac and Vascular Regeneration. Intracoronary delivery of the company's human gene fibroblast growth factor-4 (FGF-4) increased heart function and reduced the size of dilated hearts over the three-week study period. The San Diego, California-based company has licensed the gene exclusively from New York University. Collateral is also using the FGF-4 gene to develop a treatment for coronary artery disease.
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.